Antihyperglycemic Medication in HF
The treatment of diabetes mellitus in patients with acute decompensated HF presents a particular challenge because nearly two thirds of these patients have impaired renal function, which affects the safety of many AHMs used in the treatment of diabetes mellitus. 11, 12 In particular, metformin, sulfonylureas, meglitinides, incretin mimetics (glucagonlike peptide-1 receptor agonists), DPP-4 inhibitors, and α-glucosidase inhibitors carry specific cautions in their prescribing information, recommending against use or cautious dose adjustment in patients with renal impairment. Although impaired renal function is prevalent in patients hospitalized with acute decompensated HF, it is unclear how this affects the choice of AHMs for patients with diabetes mellitus. Moreover, the overall use and outcomes associated with use of AHMs with renal contraindications among HF patients are poorly understood. We performed an analysis of Get With the Guidelines-Heart Failure (GWTG-HF) linked with Medicare claims data to characterize utilization of AHMs after hospitalization for HF based on renal function.
Methods

GWTG-HF
GWTG-HF is a national-quality improvement initiative aimed at improving HF care, and details of the program have been previously published. 13, 14 Participating hospitals must receive approval through their local institutional review boards or a waiver of individual consent under the common rule. Trained personnel regularly review hospital records and identify patients admitted with HF. Medical history and demographic data are abstracted, and deidentified data are entered into a central database using a web-based patient management tool. Quintiles (Cambridge, MA) is the data collection coordination center for the American Heart Association/American Stroke Association GWTG programs. The Duke Clinical Research Institute (Durham, NC) serves as the data analysis center and has an agreement to analyze the aggregate, deidentified data for research purposes.
Study Population
Using GWTG-HF, we identified patients with HF who had either a prior medical history of diabetes mellitus or new diagnosis of diabetes mellitus established during the index HF hospitalization and were discharged from hospital between January 1, 2006, and October 1, 2011. Patients had to be continuously enrolled in Medicare feefor-service and Medicare Part D at index discharge and for the 90 days post discharge. Among a total of 61 093 Medicare beneficiaries identified in GWTG-HF during this study period, 22 873 (37.4%) had diabetes mellitus and were discharged before October 1, 2011. We excluded patients who died in hospital (n=671), transferred out of index hospital (n=587), were discharged to hospice (n=585), had end-stage renal disease (n=1387), or had transplant or left ventricular assist device (LVAD) implantation during hospitalization (n=22). Of the remaining patients, 8791/19 621 (44.8%) were enrolled in Medicare fee-for-service and Medicare Part D continuously within the 90 days post index discharge and were included in the final study population.
Statistical Analysis
Patients were classified into 3 renal function classes (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m 2 , 30≤eGFR<60 mL/ min/1.73m 2 , and eGFR ≥60 mL/min/1.73m 2 ) using the Modification of Diet in Renal Disease formula and serum creatinine on admission to hospital. Percentages and medians with 25th and 75th percentiles (interquartile ranges [IQRs]) were reported to describe the distribution of categorical and continuous variables, respectively. The patient characteristics, including demographics, clinical data, medical history, and hospital characteristics as captured in GWTG-HF, were compared between the 3 renal function groups. Pearson Chi-square and Kruskal-Wallis tests were used to test the difference for categorical and continuous variables.
To assess use of AHMs, we linked GWTG-HF data to Medicare Part D claims to identify diabetes mellitus medications filled within 90 days of index discharge for HF, including metformin/biguanide, sulfonylurea, meglitinide, glucagon-like peptide-1 agonist, DPP-4 inhibitor, α-glucosidase inhibitor, thiazolidinedione, insulin, and amylin analog. For patients with >1 hospitalization, only the first claim for AHM and its corresponding hospitalization was used for analysis. If multiple claims for one AHM class were found within 90 days, that AHM was counted only once. If a patient had claims for ≥2 medications in different AHM classes, for example, both insulin and metformin, it was counted for each of the AHM classes. AHMs with labeling to avoid or reduce dosage in CKD were categorized as renal contraindicated AHMs, including metformin, sulfonylureas, meglitinides, incretin mimetics (glucagon-like peptide-1 agonists), DPP-4 inhibitors, and α-glucosidase inhibitors. Renal contraindicated use was defined as the use of a renal contraindicated AHM among patients with eGFR <30 mL/min/1.73m 2 on admission to hospital, as captured in GWTG-HF. The trend in renal contraindicated AHM use from 2006 to 2011 was tested using Cochran-Mantel-Haenszel rowmean score statistic.
A multivariable logistic regression analysis was conducted to examine the factors associated with renal contraindicated AHM use among the patients with eGFR <30 mL/min/1.73m 2 . Generalized estimating equation methods were used to account for the within-hospital clustering of patients. The regression model included demographics, age, sex, non-Caucasian race, Hispanic ethnicity, prior medical histories (atrial fibrillation/flutter, chronic obstructive pulmonary disease, hyperlipidemia, hypertension, peripheral vascular disease, ischemic heart disease, including prior myocardial infarction, coronary artery disease, percutaneous coronary intervention, or coronary artery bypass grafting, cerebrovascular accident/transient ischemic attack, implantable-cardioverter defibrillator, HF, anemia, pacemaker, renal insufficiency, depression and smoking history in past 6 months), ejection fraction, body mass index, respiratory rate at admission and heart rate, systolic blood pressure at discharge, sodium, eGFR, blood urea nitrogen, hemoglobin at admission, potassium at discharge, length of stay, and hospital characteristics, including region, number of beds, rural (versus urban) location, and hospitals' teaching status. Most variables had missing rate <5%, except Hispanic ethnicity had 12% missing and body mass index had 13% missing and potassium had 16% missing rate. Therefore, multiple imputation was used to address missing variables.
A P value <0.05 was considered statistically significant for all tests. All analyses were performed with SAS software version 9.2 (SAS Institute, Cary, NC).
Results
Among 8791 Medicare patients with HF and diabetes mellitus included in our study, the median age was 77 (IQR 71-83), and 62.3% was female, with median ejection fraction 47% (IQR 30-60). The median body mass index was 29.7 (IQR 25.5-35.3), and median hemoglobin A1c was 6.8 (IQR 6.2-7.8). In this cohort, 17.2% had eGFR <30 mL/min/1.73m 2 , 49.1% had 30≤eGFR<60 mL/min/1.73m 2 , and 32.5% had eGFR ≥60 mL/min/1.73m 2 ( Table 1) . Patients in lower renal function classes included higher proportion of females (71.1% versus 64.9% versus 53.6%; P<0.001), more patients with multiple comorbidities (4 versus 3 versus 3; P<0.001), lower proportion of patients with reduced ejection fraction (30.4% versus 33.7% versus 36.2%; P=0.001), and slightly longer lengths of stay (5 [IQR 3-7.5] versus 4 [IQR 3-7] versus 4 days [IQR 3-6]; P<0.001).
AHM use varied considerably by renal function ( Table 2 ). The proportion of patients filling prescriptions for insulin, which is generally used as monotherapy, was higher among patients with more severe renal dysfunction (47.4% versus 40.9% versus 33%; P<0.001 among patients with eGFR <30 mL/min/1.73m 2 versus 30≤eGFR<60 mL/min/1.73m 2 versus eGFR ≥60 mL/min/1.73m 2 , respectively). In contrast, metformin use (3.5% versus 13.5% versus 29.5%) and sulfonylurea use (26.9% versus 34.3% versus 32.9%) were lower among patients with more severe renal dysfunction. Prescription fills for other AHMs were low overall, though thiazolidinediones were surprisingly used in 6.6% of patients with HF, despite the known risk for worsening HF. DPP-4 inhibitors were likewise used in 5.1% of patients overall, though there was a trend toward increased use of DPP-4 inhibitors and decreased use of thiazolidinediones among all patients over time (P<0.001; Figure 1 ). Among 1512 patients with eGFR <30 mL/min/1.73m 2 , 35.4% received renal contraindicated AHMs, though there was a trend toward less renal contraindicated AHM use over time during the study period (P=0.048; Figure 2A ). In particular, there was a temporal trend toward less sulfonylurea use (P=0.005), more DPP-4 inhibitor use (P<0.001), and less thiazolidinedione use (P<0.001; Figure 2B ). The proportion of patients with a prior history of insulin-treated diabetes mellitus was lower (32.3% versus 65.3%; P<0.001) and age slightly higher (77 [IQR 72-84] versus 76 [IQR 70-83]; P<0.005) among patients receiving renal contraindicated AHMs compared with those not (Table 3 ). There was also a slightly higher hemoglobin A1c (6.9 [IQR 6.2-7.7] versus 6.6 [IQR 6-7.3]; P=0.030) and slightly greater proportion of patients with low ejection fraction among patients receiving renal contraindicated AHMs (33.6% versus 28.7%; P=0.049). Surprisingly, patients receiving renal contraindicated AHMs had less number of comorbidities (P=0.03). Among hospital characteristics, only hospital region showed an association with renal contraindicated AHM use. We performed a multivariable logistic regression analysis to identify independent predictors of renal contraindicated AHM use, but no clinically meaningful variables were found to have clear 
Discussion
In this study, we have reported novel data regarding usage patterns of AHMs among Medicare patients with HF and diabetes mellitus. AHMs are used in ≈75% of patients with HF and diabetes mellitus, with insulin being the most commonly prescribed medication regardless of renal function class, followed by sulfonylureas and metformin. Moreover, we show that AHMs that may worsen HF, including thiazolidinediones and potentially some DPP-4 inhibitors based on data that emerged after the study period, are used in one tenth of patients with HF, and that over one third of patients with eGFR <30 mL/min/1.73m 2 are treated with renal contraindicated AHMs. There were strikingly few differences among patients receiving renal contraindicated AHMs versus not receiving renal contraindicated AHMs among patients with eGFR <30 mL/min/1.73m 2 , suggesting that provider choices, rather than patient factors, may be driving these prescribing patterns. Current guidelines provide little guidance for managing complex comorbidities, such as diabetes mellitus and CKD in HF patients, reflecting the relative paucity of data regarding management of these complex comorbidities. Where data are lacking, safety is generally the primary driver for prescribing, yet we showed that 35.4% of prescriptions for AHMs among patients with diabetes mellitus and eGFR <30 mL/min/1.73m 2 are renal contraindicated, thereby potentially exposing patients to a higher risk of adverse events, particularly hypoglycemia. We suspect that this reflects a lack of awareness regarding the safe use of various AHM classes among patients with diabetes mellitus and CKD. Moreover, we observed an ≈10% prescription rate for AHMs that may worsen HF. Although data regarding the potential increased risk of HF with the DPP-4 inhibitor saxagliptin did not emerge until 2013, data regarding the HF risk with thiazolidinediones were available throughout most of the study period. 7, 15 The impact of renal contraindicated AHM prescription on healthcare utilization and outcomes are poorly understood and need further investigation. This is particularly important because HF patients are prone to fluctuations in renal function because neurohormonal and hemodynamic derangements, volume status, and even the medicines used to treat HF or concomitant comorbidities can have significant effects on renal function and clearance of AHMs. Although it is possible that renal contraindicated AHMs were being used as a strategy to obtain better glycemic control (hemoglobin A1c 6.9 versus 6.6 among patients with renal contraindicated AHM versus not), glycemic control was good overall, and data are mixed regarding blood glucose control and HF outcomes. Though some data suggest improvement in diastolic dysfunction with enhanced blood glucose control, large randomized trials have shown higher risks of hypoglycemia with intensive blood glucose control strategies, without improvements in macrovascular outcomes or incident HF. [18] [19] [20] As such, we need more data to guide diabetes mellitus management strategies for patients with HF, including specific glycemic control targets and recommendations for medication choices, especially among patients with CKD who are prone to adverse medication effects from renal contraindicated AHMs.
Unfortunately, the optimal diabetes mellitus treatment strategy among patients with HF is unclear, even among patients without CKD. Thiazolidinediones have been shown to increase risk of HF in case reports from as early as 2002, which has been supported by clinical trial and observational data, and led to a Food and Drug Administration-issued black box warning in 2007 against their use in HF patients. 5, [21] [22] [23] [24] Observational studies suggest that insulin and sulfonylureas may be associated with higher risks for fluid retention and HF, respectively, and the initial results of the Functional Impact of GLP-1 for Heart Failure Treatment trial (FIGHT) trial suggest that liraglutide provides no cardiovascular outcome benefit to [15] [16] [17] Information regarding potential HF risk for DPP-4 inhibitors was not available until late 2013. 7 8, 28, 29 These studies did not specifically enroll HF patients, and the TECOS trial excluded patients with eGFR <30 mL/min/1.73m 2 . Nevertheless, saxagliptin patients with CKD had a greater risk for HF. 7, 8 Metformin potentially has the best observational data supporting its use in HF patients, but it continues to carry warnings against its use in CKD patients, despite evidence suggesting that it may be cautiously used in setting of mild to moderate CKD. 30, 31 Unfortunately, there is little data on how CKD affects HF risk among other AHMs. Although choice of an optimal AHM in HF patients is not straightforward, it should be noted that thiazolidinediones were prescribed in ≥3% of patients during the last 2 years of our study, despite strong evidence against their use. Moreover, 32.3% of patients who received renal contraindicated AHMs were also prescribed insulin.
Despite a growing body of knowledge addressing the complex interplay between metabolic derangements of HF and diabetes mellitus, a safe and effective AHM remains elusive. 32, 33 The sodium-glucose cotransporter-2 inhibitor empaglaflozin may be promising based on the recent results of Empaglaflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), which showed a lower risk of HF hospitalization (hazard ratio 0.65) and death from cardiovascular causes (hazard ratio 0.62). 34 Unfortunately, sodium-glucose cotransporter-2 inhibitor use was not assessed in this study because it was not Food and Drug Administration-approved during the study period. Additional studies are underway to assess cardiovascular outcomes with nearly all classes of AHMs. 35 Nevertheless, these trials are not specifically designed to recruit HF patients, and many limit enrollment of patients with CKD, so we think that there needs to be more dedicated trials of AHMs specifically for HF patients with complex comorbidities, such as CKD.
This study has several limitations that must be mentioned. GWTG-HF is a voluntary, quality-improvement program and may not represent prescribing patterns at nonparticipating hospitals. Also, care for patients with Medicare and Part D may differ from care of younger patients in different care settings. It is possible that renal function at baseline in our patients with acute decompensated HF did not reflect baseline outpatient renal function; nevertheless, we think that our results are still applicable to a broad population of patients because labile renal function should itself be considered when prescribing AHMs with renal contraindications to mitigate risks of adverse drug effects. In addition, AHM use was assessed in the first 90 days after hospital discharge. We were, therefore, unable to capture if AHM therapy was altered by outpatient providers after this time frame or if patients continued to fill prescriptions for AHMs. It should be noted that nearly one quarter of patients failed to fill a prescription for AHM, regardless of renal function class, which could signify either lack of adherence, diet control, or sufficient preexisting supply of AHMs. Because of limitations of data, we are unable to identify whether factors that are not captured in GWTG-HF may have affected choice and safety of AHMs used to treat patients in this study. Finally, these data are observational and hypothesis generating. Although nearly one third of AHMs prescribed among patients with eGFR <30 mL/min/1.73m 2 have renal contraindications, further research is needed to assess how this affects outcomes.
In conclusion, AHMs are used in a majority of patients with HF and diabetes mellitus, though a considerable proportion of prescriptions are renal contraindicated or thought to exacerbate HF. There is a strong need to increase awareness among both providers and patients to prevent and investigate the incidence and impact of adverse events based on these prescribing patterns. Moreover, there are few data to guide management of diabetes mellitus in the setting of comorbid HF and CKD. Future clinical trials are needed to assess outcomes among patients receiving specific classes of AHMs, including renal contraindicated AHMs. Categorical variables are presented as percentages, and continuous variables are presented as medians (interquartile ranges). ACE/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AHM, antihyperglycemic medication; CKD, chronic kidney disease; Cr, creatinine; CVA/TIA, cerebrovascular accident/transient ischemic attack; eGFR, estimated glomerular filtration rate; GWTG-HF, Get With the Guidelines Heart Failure; and HbA1c, hemoglobin A1c. 
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